RE:Big Pharma couldn't do it...Looking back to Monday there was a large offering of about 400K at 38 cents and memory serves me it was TD. Now they did back off later but the stock never went higher and it's the same pattern of when there were PPs at 18 cents, they let the stock 'run' to between 22-23 cents. TD caps it, sells some, later sells it down and then we get the PP. It's always TD led and we always get the doom and gloom crowd just before getting the PP news. So it makes perfect sense there is a PP coming at 30 cents. It also makes perfect sense that given the amount they usually raise that it's needed short term but it doesn't mean there is a delay.
Being objectively critical is one thing but floating negative rumors of delays and reverse splits is why certain people should be ignored.
wildbird1 wrote: The last two weeks were very interesting.
1) The SP did increase by 100%, nobody know exactly why, but because of that 100%, TLT did get some visibility, as a result new investors started a position in TLT.
2) The SP did retract, nobody on this board did expect a 100% increase without some investors taking a profit.
3) Today the SP is still 53% higher than it was before it all started (not bad).
4) Ours most annoying poster (posting +15 useless posts each day), has finally openly admitted that he was a full-fledged basher and a penny flipper(although the longs on this board already knew he was).
Question?
Will the SP continue to decrease?
Answer.
It doesn't matter, the FDA doesn't care about the SP, the FDA care only about the data, and TLT data are rock solid.
Merck's(+200 billion market cap).
Merck's has Keytruda, with a very low 19CR%, and a ton of side effects.
Johnson &Johnson(+400 billion market cap).
J&J has Tar-200 with an anemic 4.7CR% on the long term.
Note:
TLT management with a shoestring budget did better than the biggest Pharma Company in the world.
The above could explain why bashers keep trying to discredit TLT management.
Keep in mind...as we speak, with the best data in the business, TLT has a big foot inside the FDA, and TLT is working hand in hand with the FDA to approve this much needed '' one and done '' treatment for BCG resistant patients.
For now, forget about the SP fluctuations(you have no control over it), and focus on TLT rock solid data, and the fact that TLT is the only Pharmaceutical Company in the world that has a very good '' one and done'' treatment for BCG resistant patients in a FDA phase11 trial, and to top it off, TLT has the most impressive data in the business.
Financing.
Financing is TLT management job, and up until now management has always found ways to finance TLT, and that will not change.
Extra note:
-ImmunityBio has Anktiva, a 37 months long treatments that doesn't even cure the Bladder Cancer.
-ImmunityBio has a $7.40can SP, and analys't have a $40.can SP projection for ImmunityBio.
-ImmunityBio has a huge 700 million shares out, and there is no talk of a 1 for 3 reverse.... :) :) :) :).....:):):)...:):):)...........
-TLT has 240 million shares out(+300 million fully diluted).
All in all not a bad two weeks.
Hang tight, the best has yet to come.
I love my TLT shares.
.